Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
Active, not recruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
May 20, 2023
Primary Completion Date
October 1, 2024
Study Completion Date
February 1, 2025
Conditions
Breast Cancer
Trial Locations (1)
200032
Fudan University Shanghai Cancer Center, Shanghai
All Listed Sponsors
lead
Fudan University
OTHER
NCT06344780 - Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter